Skip to main navigation
Skip to content
Contact Us
Millendo
  • Our Story
  • Our Patients
    • Clinical Research Overview
    • Livoletide Pivotal Study
    • Nevanimibe Clinical Study
    • Educational Resources and Advocacy
    • Compassionate Use
  • Our Science
    • Pipeline
    • Disease Areas
    • Livoletide
    • Nevanimibe
    • MLE-301
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports & SEC Filings
    • Investor Resources
  • Join Our Team
Contact Us
Millendo
  • Our Story
  • Our Patients
    • Clinical Research Overview
    • Livoletide Pivotal Study
    • Nevanimibe Clinical Study
    • Educational Resources and Advocacy
    • Compassionate Use
  • Our Science
    • Pipeline
    • Disease Areas
    • Livoletide
    • Nevanimibe
    • MLE-301
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports & SEC Filings
    • Investor Resources
  • Join Our Team
IR Contact
  • Investor FAQs
  • IR Contact
  • Email Alerts

IR Contact

Stephanie Ascher
Phone: 212-362-1200
E-mail: stephanie.ascher@sternir.com

Shareholder Tools

Print Page Email Page RSS Feeds Email Alerts Financial Tear Sheet

US Offices

Corporate Headquarters

110 Miller Avenue, Suite 100
Ann Arbor, MI 48104
734-845-9000
millendo@millendo.com

Lexington Office

420 Bedford Street,
Suite 260
Lexington, MA 02420

Europe Office

 
Lyon Office

Millendo Therapeutics SAS
c/o Canopee consulting
8 rue Berjon
69009 Lyon
France
Tel +33 472 18 94 28

  • Our Story
  • Our Patients
  • Our Science
  • Investors & Media
  • Join Our Team
  • Privacy Policy
Copyright © 2020 Millendo Therapeutics, Inc. All rights reserved.
Scroll to Top